t
Celadon Pharmaceuticals Plc announced the admission of 2,625,000 new ordinary shares to trading on AIM on September 17, 2024. Following this admission, the Company's issued share capital and total voting rights now comprise 68,845,807 Ordinary Shares.
| Date | 17 Sept 2024 |
| Time | 09:28:59 |
| Category | Capital structure |
| ID | 5064E |
Celadon Pharmaceuticals Plc
("Celadon" or the "Company" or the "Group")
Admission of Shares and Total Voting Rights
London, 17 September 2024 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, is pleased to announce that further to the announcement on 11 September 2024, application for the admission of 2,625,000 new ordinary shares to trading on AIM (the "Admission") has been made and 2,625,000 new ordinary shares were admitted to trading today.
The Company advises that on Admission the Company's issued share capital will consist of 68,845,807 Ordinary Shares, with one voting right each. The Company does not hold any shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company will be 68,845,807. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
|
|
|
|
Celadon Pharmaceuticals Plc |
|
|
James Short Jonathan Turner |
Via Sodali & Co |
|
|
|
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Bobbie Hilliam / Andrew Potts |
+44 (0)20 7523 8000 |
|
|
|
|
Global Investment Strategy UK Limited (Joint Broker) James Sheehan |
+44 (0)20 7048 9400 |
|
|
|
|
Sodali & Co |
|
|
Elly Williamson / Sam Austrums / Nick Johnson |
+44 (0)20 7250 1446
|
|
|
|
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder.
For further information please visit our website www.celadonpharma.co.uk